Hemab Therapeutics

Hemab - A bleeding disorder company

Cambridge · Founded 2019 · $347.0M raised

Headquarters
Cambridge
Employees
11–50
Founded
2019
Business Model
B2B
Website
hemab.com
Total Funding
$347.0M
Last Round
$157.0M Series CMar 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Hemab Therapeutics is a clinical-stage biopharmaceutical company developing novel prophylactic therapies for serious, underserved bleeding and thrombotic disorders. Its lead program, sutacimig, is a bispecific antibody in Phase 2 trials for Glanzmann Thrombasthenia, and HMB-002 targets Von Willebrand Disease. Founded in 2019 by former Novo Nordisk researchers and backed by Novo Holdings, the company is advancing a pipeline aimed at enabling prevention rather than just management of rare bleeding conditions.

Summary

Hemab Therapeutics is a Biotech company based in Cambridge, founded in 2019. It has raised $347.0M in total across 3 rounds, most recently a $157.0M Series C round in Mar 2026. Investors include Sofinnova Partners, Access Industries and Novo Holdings A/S.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CMar 2026
$157.0M

Sign up to see all 3 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Hemab Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/hemab-therapeutics"><img src="https://indexed.vc/api/badge/company/hemab-therapeutics" alt="Hemab Therapeutics on Indexed.vc" width="260" height="76" /></a>